Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13106155 | 1.00 | L3MBTL1 (0.62) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL30734745 | 0.88 | L3MBTL1 (0.51) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL19586107 | 0.88 | L3MBTL1 (0.51) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL29094193 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL3532423 | 0.83 | L3MBTL1 (0.46) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL29741986 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL12193567 | 0.83 | L3MBTL1 (0.63) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL30628634 | 0.81 | L3MBTL1 (0.62) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| SCHEMBL14908618 | 0.81 | L3MBTL1 (0.62) | L3MBTL1CNR2MAPTMEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27978075 | 0.81 | L3MBTL1 (0.62) | L3MBTL1CNR2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | PROTEGO BIOPHARMA INC (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382292-A1 | COMPOUNDS FOR TREATING LIGHT CHAIN AMYLOIDOSIS | TTR, CRYAA, BCL6 | L3MBTL1 2798/4885CNR2 4403/4885MAPT 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.